Shuaixiang Zhou

Suzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity.

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity.

Journal: Cancer research

Published: December 05, 2025

A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism.

A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism.

Journal: Molecular cancer therapeutics

Published: April 13, 2025

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.

Journal: Virology journal

Published: March 26, 2025

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities.

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities.

Journal: Nature communications

Published: February 19, 2025

Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models.

Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models.

Journal: Cancer immunology, immunotherapy : CII

Published: January 08, 2024

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells.

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells.

Journal: Nature cancer

Published: October 25, 2022

Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy.

Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy.

Journal: International journal of biological macromolecules

Published: September 04, 2022

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.

Journal: Cancer immunology, immunotherapy : CII

Published: March 18, 2022

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.

Journal: Cell reports. Medicine

Published: December 08, 2021

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.

Journal: The Journal of clinical investigation

Published: September 13, 2021

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.

Journal: Oncoimmunology

Published: July 09, 2021

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.

Journal: Cancer immunology, immunotherapy : CII

Published: September 15, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026